Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1680
    +0.0024 (+0.20%)
     
  • GBP/USD

    1.2495
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    51,239.46
    -471.75 (-0.91%)
     
  • CMC Crypto 200

    1,332.84
    -63.69 (-4.56%)
     
  • S&P 500

    5,109.48
    +61.06 (+1.21%)
     
  • DOW

    38,327.49
    +241.69 (+0.63%)
     
  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Siemens Healthineers AG (ETR:SHL) Investors Are Paying Above The Intrinsic Value

Does the share price for Siemens Healthineers AG (XTRA:SHL) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Also note that this article was written in May 2018 so be sure check the latest calculation for Siemens Healthineers here.

What’s the value?

I will be using the 2-stage growth model, which takes into account the initial higher growth stage of a company’s life cycle and the steadier growth phase over the long run. To begin, I pulled together the analyst consensus estimates of SHL’s levered free cash flow (FCF) over the next five years and discounted these values at the cost of equity of 8.76%. This resulted in a present value of 5-year cash flow of €6.65B. Keen to know how I arrived at this number? Take a look at our detailed analysis here.

XTRA:SHL Future Profit May 28th 18
XTRA:SHL Future Profit May 28th 18

The graph above shows how SHL’s earnings are expected to move in the future, which should give you some color on SHL’s outlook. Secondly, I determine the terminal value, which is the business’s cash flow after the first stage. It’s appropriate to use the 10-year government bond rate of 2.8% as the perpetual growth rate, which is rightly below GDP growth, but more towards the conservative side. The present value of the terminal value after discounting it back five years is €17.86B.

ADVERTISEMENT

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is €24.51B. The last step is to then divide the equity value by the number of shares outstanding. This results in an intrinsic value of €24.51, which, compared to the current share price of €33.4, we find that Siemens Healthineers is rather overvalued at the time of writing.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For SHL, I’ve compiled three key factors you should further examine:

  1. Financial Health: Does SHL have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.

  2. Future Earnings: How does SHL’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of SHL? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow for every stock on the XTRA every 6 hours. If you want to find the calculation for other stocks just search here.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.